This Month, Triple Your Impact
This Month, Triple Your Impact
Make 3x the difference during Alzheimer’s & Brain Awareness Month with our 3x Bonus Match Challenge — but only until midnight June 16. Your gift can go three times as far to help provide care and support and advance research.
Donate NowAlzheimer’s Association Fuels Global Treatment Breakthroughs with $10M Venture Fund Investment
For the first time, more than 7 million Americans are living with Alzheimer's disease. This commitment is a crucial part of the Association’s mission to lead the way to end Alzheimer’s and all other diseases that cause dementia through the acceleration of global research.
“Every investment we make is a reaffirmation of our commitment to pioneering research that will one day eliminate Alzheimer’s and all other dementias,” said Joanne Pike, DrPH, president and CEO of the Alzheimer’s Association. “Our $10 million investment, coupled with active participation on the DDF-2 Scientific Advisory Board, underscores our dedication to accelerating the development of novel therapeutics that offer hope for millions of families affected by these devastating diseases.”
“This venture capital fund is particularly exciting because of the wide range of experienced and successful partners across multiple neurodegenerative diseases and various stakeholder industries, with a focus on transformational science,” Pike added.
“We’re honored to welcome the Alzheimer’s Association as an investor in our second fund,” said Christian Jung, Partner at SV Health Investors and co-leader of the Dementia Discovery Fund. “Partnering with the world’s leading organization in Alzheimer’s care, support, and research strengthens our shared commitment to accelerating the development of transformative therapies. Together, we aim to change the future for millions of people affected by dementia.”
This new investment drives progress across a spectrum of clinical trials, from seed and early-stage research to late-stage developments and further strengthens the Alzheimer’s Association’s robust research funding portfolio on a global scale. Through its Part the Cloud initiative which fuels early-stage clinical research, the Association has raised more than $85 million and funded 68 innovative clinical trials to advance and diversify the dementia drug development pipeline. These projects have attracted more than $1.6 billion in additional funding from government and other sources, underscoring the potential of this integrated approach to drive change.
DDF-2, managed by SV Health Investors, which closed with commitments totaling $269 million, is leading transatlantic venture capital funding to continue its successful investment strategy focused on dementia.
The Alzheimer’s Association is committed to advancing research from discovery through all clinical stages, ensuring that innovative therapies reach those in need faster than ever before. In April 2023, the Alzheimer’s Association announced a commitment of €10 million to EQT Life Sciences’ LSP Dementia Fund, an international venture capital fund that invests in companies developing promising, high-impact treatments for Alzheimer’s and other neurodegenerative diseases.
About the Alzheimer's Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.